Vertex Pharmaceuticals Incorporated (BMV:VRTX)

Market Cap	2.05T -10.3%
Revenue (ttm)	215.03B +10.3%
Net Income	67.41B
EPS	260.87
Shares Out	n/a
PE Ratio	30.46
Forward PE	23.10
Dividend	n/a
Ex-Dividend Date	n/a

Volume	311
Average Volume	341
Open	8,117.40
Previous Close	7,984.69
Day's Range	8,117.40 - 8,117.40
52-Week Range	6,800.00 - 10,318.00
Beta	0.32
RSI	52.69
Earnings Date	Feb 12, 2026

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The com...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1989
• Employees: 6,100
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: VRTX

Financial Performance

Financial numbers in USD